Non-Small-Cell Lung Clinical Trials

41 recruitingLast updated: June 17, 2026

There are 41 actively recruiting non-small-cell lung clinical trials across 47 countries. Studies span Phase 2, Phase 1, Phase 3, Not Applicable. Top locations include Barcelona, Spain, Madrid, Spain, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


Non-Small-Cell Lung Trials at a Glance

41 actively recruiting trials for non-small-cell lung are listed on ClinicalTrialsFinder across 6 cities in 47 countries. The largest study group is Phase 2 with 19 trials, with the heaviest enrollment activity in Barcelona, Madrid, and Houston. Lead sponsors running non-small-cell lung studies include Pfizer, AstraZeneca, and Allist Pharmaceuticals, Inc..

Browse non-small-cell lung trials by phase

Treatments under study

About Non-Small-Cell Lung Clinical Trials

Looking for clinical trials for Non-Small-Cell Lung? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Non-Small-Cell Lung trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Non-Small-Cell Lung clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 41 trials

Recruiting
Phase 1Phase 2

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer (NSCLC)Non-small Cell Lung CancerCarcinoma, Non-Small Cell Lung+1 more
National Cancer Institute (NCI)60 enrolled1 locationNCT06694454
Recruiting
Phase 1Phase 2

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Non-Small-Cell Lung Carcinoma
AbbVie252 enrolled102 locationsNCT06772623
Recruiting
Phase 1

First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

Advanced Solid TumorMetastatic Solid TumorEsophageal Squamous Cell Carcinoma+7 more
Plexium, Inc.155 enrolled10 locationsNCT07284186
Recruiting

A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China

Non-Small-Cell Lung
AstraZeneca3,000 enrolled1 locationNCT07316062
Recruiting
Phase 1

A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

Head and NeckHead and Neck Squamous Cell Carcinoma (HNSCC)Head and Neck Cancer+12 more
EpiBiologics110 enrolled6 locationsNCT07462377
Recruiting
Phase 2

A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)

Squamous Non-small-cell Lung Cancer
Merck Sharp & Dohme LLC180 enrolled51 locationsNCT07221474
Recruiting

Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib

Lung AdenocarcinomaDepressionCognitive Dysfunction+3 more
Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo24 enrolled1 locationNCT07633626
Recruiting
Phase 2

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

Non-small Cell Lung CancerLung NeoplasmsCarcinoma+6 more
Pfizer120 enrolled3 locationsNCT07489066
Recruiting
Phase 3

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Lung CancerNon-small Cell Lung CancerCarcinoma, Non-Small Cell Lung+3 more
Pfizer1,410 enrolled346 locationsNCT07222566
Recruiting
Phase 2

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

Non-small Cell Lung CancerMetastatic Squamous Non-Small Cell Lung CarcinomaNon-Small Cell Lung Cancer (Stage III)+5 more
Genelux Corporation142 enrolled15 locationsNCT06463665
Recruiting

A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea

Non-Small-Cell Lung Carcinoma
Novartis Pharmaceuticals44 enrolled10 locationsNCT05703516
Recruiting

Prospective Cohort Study Evaluating 18FDG PET-CT for the Early Prediction of the Efficacy of Immunotherapy Associated or Not With Chemotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Broncho-Pulmonary Carcinoma

Carcinoma, Non-Small-Cell Lung (NSCLC)
Centre Antoine Lacassagne200 enrolled1 locationNCT06833229
Recruiting

NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations

Non-squamous Metastatic Non-Small-Cell Lung Carcinoma
AstraZeneca600 enrolled29 locationsNCT06494540
Recruiting
Phase 1Phase 2

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

Breast CancerOvarian CancerEndometrial Cancer+2 more
AstraZeneca460 enrolled67 locationsNCT05123482
Recruiting
Not Applicable

Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context

ALK+ Non-Small-Cell Lung Carcinoma
Pfizer90 enrolled31 locationsNCT06487078
Recruiting
Phase 2

Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment

Renal Cell Carcinoma (RCC)Small Cell Lung CancerNon-Small-Cell Lung
Advenchen Pharmaceuticals, LLC.80 enrolled7 locationsNCT05363280
Recruiting

Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)Non-small Cell Lung CancerNSCLC+6 more
GFPC Investigation100 enrolled16 locationsNCT07563205
Recruiting
Phase 3

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer MetastaticNon-Small-Cell Lung CarcinomaNon-small Cell Carcinoma
Pfizer680 enrolled305 locationsNCT07144280
Recruiting
Phase 1

Phase 1 Study of PF-08046033 in Advanced Solid Tumors

Esophageal CancerCutaneous MelanomaNon-Small-Cell Lung
Pfizer250 enrolled6 locationsNCT07519655
Recruiting
Phase 3

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Non-small Cell Lung CancerCarcinoma, Non-Small Cell LungCarcinoma, Non-Small-Cell Lung (NSCLC)
Pfizer714 enrolled329 locationsNCT06758401